Discover
CALC
CalciMedica, Inc.
1.04
12 x 1.11
1 x 0.97
bid
ask
+
0.01
0.97%
7 @ 06:16 AM
1.01 -0.03 (2.88%)
| Ytd | -84.22% | |
| 1y | -33.33% |
0.98
day range
1.15
0.46
52 week range
7.20
| Open | 0.98 | Prev Close | 1.03 | Low | 0.98 | High | 1.15 | Mkt Cap | 16.43M |
| Vol | 935.33K | Avg Vol | 1.26M | EPS | -1.31 | P/E | N/A | Forward P/E | -1.69 |
| Beta | 1.20 | Short Ratio | 1.68 | Inst. Own | 43.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.74 | 200-d Avg | 2.28 | 1yr Est | 17.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.61 | -0.5 | 0.11 | 18.03% |
| 2024-08-12 | 2024-06 | -0.55 | -0.52 | 0.03 | 5.45% |
| 2024-08-12 | 2024-06 | -0.55 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.5 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.5 | -0.43 | 0.07 | 14.00% |
| 2024-03-28 | 2023-12 | -1 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-17 | LUCID CAPITAL MARKETS | Upgrade | Buy | |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-10 | Oppenheimer | Upgrade | Outperform | Outperform |
| 2024-07-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-05-30 | BJERKHOLT ERIC H | Director | 3.68K | Purchase |
| 2024-09-08 | DUNN MICHAEL JOHN | President | 11.76K | Conversion of Exercise of derivative security |
| 2023-11-02 | HEBBAR SUDARSHAN | Officer | 46.00K | Purchase |
| 2024-10-31 | LEHENY A RACHEL | Chief Executive Officer | 871.25K | Purchase |
| 2024-12-05 | MIDDLETON FRED A | Director and Beneficial Owner of more than 10% of a Class of Security | 2.45M | Purchase |
| 2024-10-31 | ROBERTS ERIC W | Officer, Director and Beneficial Owner | 974.81K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Deerfield Management Company, L.P. (Series C) | 1000.00K | 2.76M | 17.66% |
| 2024-09-29 | Soleus Capital Management, L.P. | 783.90K | 2.16M | 13.85% |
| 2024-09-29 | Aisling Capital Management LP | 521.11K | 1.44M | 9.20% |
| 2024-09-29 | Vanguard Group Inc | 254.15K | 701.45K | 4.49% |
| 2024-09-29 | BML Capital Management, LLC | 153.89K | 424.73K | 2.72% |
| 2024-09-29 | Geode Capital Management, LLC | 66.55K | 183.69K | 1.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 226.18K | 624.27K | 3.99% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 33.31K | 91.94K | 0.59% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 27.97K | 77.18K | 0.49% |
| 2024-10-30 | iShares Micro Cap ETF | 14.55K | 40.14K | 0.26% |
| 2024-10-30 | Fidelity Total Market Index Fund | 11.76K | 32.45K | 0.21% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 8.04K | 22.18K | 0.14% |